We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Latest Generation Random Analyzer System Unveiled at the AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 01 Aug 2013
The latest generation random access clinical chemistry and immunochemistry analyzer is receiving its debut at the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013.

The Siemens Healthcare Diagnostics (Tarrytown, NY, USA) is unveiling the advanced VersaCell X3 system at the Clinical Lab Expo. More...


The newest model of Siemens’s longstanding VersaCell System, the new VersaCell X3 Solution now offers the benefits of automation without the space or budget considerations of a track-based system. VersaCell X3 Solution’s arrival compliments the recent launch of the Siemens Aptio Automation platform, designed for the growing needs of medium- to very high-volume laboratories.

The VersaCell X3 Solution delivers several advantages. The new platform maintains its small footprint and upright design, but now connects up to three Siemens analyzers through a single robotic sample interface for increased productivity gains. By supporting a customized mix of chemistry, immunoassay and/or integrated systems and associated assay menus, VersaCell X3 Solution helps labs to reduce operator sample handling, better prioritize staff work and eliminate pre- and post-analytical processing—all through one-touch sample management.

A new priority drawer on the VersaCell X3 Solution provides eight new STAT positions and frees up 50 sample positions for routine processing, enhancing STAT management and increasing overall sample routing flexibility. Modifications to VersaCell X3 Solution’s signature robotic arm also enable it to support both rounded and flat-bottom tubes, and the incorporation of a docking plate reduces service intervention time for all connected systems. A centralized screen on VersaCell X3 Solution provides consolidated, single-operator access to all connected analyzers, and further data consolidation is achievable through a connection to Siemens’ CentraLink Data Management System.

“Siemens strives to be a trusted partner for labs of all sizes and central to that goal is helping them identify and capitalize on their workflow excellence potential,” said Dave Hickey, CEO of the IT Business Unit at Siemens Healthcare Diagnostics. “The introduction of VersaCell X3 Solution is yet another way Siemens delivers on this mission through its ability to help labs streamline nonautomated environments and enhance operational efficiency, all at a cost they can justify.”

Related Links:
Siemens Healthcare Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.